STATIN USE IMPROVES OVERALL SURVIVAL IN ESOPHAGEAL ADENOCARCINOMA PATIENTS UNDERGOING CURATIVE-INTENT THERAPY. luis.santoscastro@mail.mcgill.ca

315-05

STATIN USE IMPROVES OVERALL SURVIVAL IN ESOPHAGEAL ADENOCARCINOMA PATIENTS UNDERGOING CURATIVE-INTENT THERAPY.

5

Canada

Oral or Poster

Esophageal cancer is the eleventh most common cause of cancer and the seventh cause of cancer-related mortality worldwide. Advances in detection, multimodality therapy, and surgical technique have improved long-term survival, but a paradigm-shifting advance is yet to be seen. New approaches and potential contributors are in demand. Statins are ubiquitous cholesterol-lowering oral agents. Past studies have shown their pleiotropic effects mediated by epigenetic modulation, and their use has been linked to improved survival in the cancer population.

Retrospective observational study from prospectively collected database on the impact of the concomitant use of statins during curative-intent therapy for esophageal adenocarcinoma between June 2007 and December 2023. We hypothesized that the use of statins would be associated with improved overall survival and sought to correlate statin use with pathological response prognostication categories.

Four hundred and fifty patients were included in the analysis. Groups were defined by statin use, observed in 28.4% of patients. No difference was seen between groups in Charlson comorbidity index and pathological response grade categories. Statin users were older (68.5 years old vs 63.6), had higher BMI (28.0 vs 26.3), and a higher proportion of ASA score 3 (72.2% vs 55.9%). A significant 5-year survival difference was observed favouring statin use (54.1% vs 40.7%, HR 0.69, p=0.019).

Our study shows an increase in overall survival at 5 years in statin users undergoing curative intent therapy for esophageal adenocarcinoma. This effect is independent of pathological response to systemic therapy.